These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7196236)

  • 41. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of food on the bioavailability of cyclandelate from commercial capsules.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
    Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation into 3.5.5-trimethylcyclohexyl mandelate cyclospasmol.
    EIJKEL G; ERNSTING MJ; REKKER RF; NAUTA WT
    Pharm Weekbl; 1956 May; 91(10):349-58. PubMed ID: 13335486
    [No Abstract]   [Full Text] [Related]  

  • 44. Influences of dimethindene maleate in a new formulation on oculo and psychomotor performance using the oculodynamic test (ODT) in volunteers.
    Schaffler K; Wauschkuhn CH; Martinelli M; Rehn D; Brunnauer H
    Agents Actions; 1994 Jun; 41 Spec No():C136-7. PubMed ID: 7976801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of cyclandelate on diabetic peripheral neuropathy.
    Canal N; Comi G; Marchettini P; Pozza G
    Br J Clin Pract Suppl; 1984; 34():62-8. PubMed ID: 6430326
    [No Abstract]   [Full Text] [Related]  

  • 46. Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam.
    Schaffler K; Kauert G; Wauschkuhn CH; Klausnitzer W
    Arzneimittelforschung; 1989 Feb; 39(2):276-83. PubMed ID: 2567171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific effects of cyclandelate on memory.
    Ananth J
    Drugs; 1987; 33 Suppl 2():97-102. PubMed ID: 3622311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers.
    Schaffler K; Klausnitzer W
    Pharmacopsychiatry; 1989 Jan; 22(1):26-33. PubMed ID: 2565582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial.
    Schellenberg R; Todorova A; Wedekind W; Schober F; Dimpfel W
    Neuropsychobiology; 1997; 35(3):132-42. PubMed ID: 9170118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemical synthesis of dual-radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells.
    White DA; Heffron F; Miciak A; Middleton B; Knights S; Knight D
    Xenobiotica; 1990 Jan; 20(1):71-9. PubMed ID: 2327109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multifocal infarct dementia treated by cyclandelate and monitored by quantitative EEG.
    Harding GF; Hall P; Young J; Smith GA
    Angiology; 1978 Feb; 29(2):139-40. PubMed ID: 347986
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
    de Halleux F
    Drugs; 1987; 33 Suppl 2():114-9. PubMed ID: 3622305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment of peripheral vascular diseases with cyclospasmol (mandelic acid ester of 3, 5, 5-trimethylcyclohexanol).
    VAN WIJK TW
    Angiology; 1953 Apr; 4(2):103-13. PubMed ID: 13040814
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cyclospasmol (mandelic acid ester of 3,5,5-trimethylcyclohexanol) in therapy of skin diseases].
    DOORNINK FJ
    Geneeskd Gids; 1953 Jun; 31(12):247-51. PubMed ID: 13083900
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders.
    Albizzati MG; Bassi S; Sbacchi M; Frattola L
    Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327
    [No Abstract]   [Full Text] [Related]  

  • 57. [Use of a product of esterification of mandelic acid with 3,5,5-triethylcyclohexanol (cyclospasmol) in the treatment of peripheral arteriopathy].
    STARACE G; NOFERI A; PADULA R
    Gazz Med Ital; 1960 Apr; 119():133-6. PubMed ID: 13833815
    [No Abstract]   [Full Text] [Related]  

  • 58. The clinical efficacy of Cyclospasmol: a review of the literature.
    Blakemore CB
    Br J Clin Pract Suppl; 1984; 34():3-9. PubMed ID: 6430319
    [No Abstract]   [Full Text] [Related]  

  • 59. Investigation on spasmolytics. IX. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate). (IV).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Aug; 12():853-7. PubMed ID: 13890670
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.